Esophageal adenocarcinoma (EAC) is an often deadly cancer with an incidence in Western countries that has continued to rise in the past few decades.1,2 In 2004, 8000 incidences of EAC occurred in the United States, representing a 2- to 6-fold increase in the past 20 years.3 In general, EAC affects Caucasian men (men are affected 6 to 8 times > women, and Caucasians 3 to 4 times > African-Americans) in their 50s to 60s, with an annual increase of 4% to 10% since the 1970s, making EAC the fastest rising malignancy among white men in the United States.2,4,5 Risk factors include both genetic and environmental factors, including central obesity, smoking, and diet.2,6 The 5-year survival rate for esophageal and gastroesophageal junction cancers is low at only 15% to 20%.7
Chronic gastroesophageal reflux disease is associated with the metaplastic transformation of normal squamous epithelium to specialized intestinal metaplasia within the esophagus (Barrett's esophagus).1 This premalignant condition of Barrett's esophagus can progress to low-grade dysplasia (LGD) or high-grade dysplasia (HGD), and in some cases to EAC.8 Gastroesophageal reflux disease affects approximately 20% of adults in the United States,9 with Barrett's esophagus diagnosed in 10% to 15% of these patients with reflux disease who undergo endoscopy, and 5.6% of patients without chronic reflux symptoms.10 However, patients without chronic reflux may also develop Barrett's esophagus, suggesting the presence of multiple associated risk factors.11 Currently, Barrett's esophagus is the only recognized pathologic precursor to EAC.12 Barrett's esophagus is associated with a 0.50% to 0.75% risk of progressing to EAC per year, with the greatest risk in patients with dysplastic Barrett's. Because esophagectomy may be associated with significant morbidity, endoscopic therapies for premalignant Barrett's esophagus and early EAC have been developed and studied.
Forman D. Re: the role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:1013–1014; author reply 1014.
Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049–2053.
Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287–1289.
Beddy P, Howard J, McMahon C et al.. Association of visceral adiposity with oesophageal and junctional adenocarcinomas. Br J Surg 2010;97:1028–1034.
Sharma P, McQuaid K, Dent J et al.. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004;127:310–330.
Camilleri M, Dubois D, Coulie B et al.. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005;3:543–552.
Rex DK, Cummings OW, Shaw M et al.. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670–1677.
Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002;123:461–467.
Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710–717.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–1474.
Mandal RV, Forcione DG, Brugge WR et al.. Effect of tumor characteristics and duplication of the muscularis mucosae on the endoscopic staging of superficial Barrett esophagus-related neoplasia. Am J Surg Pathol 2009;33:620–625.
Leers JM, Demeester SR, Oezcelik A et al.. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma: a retrospective review of esophagectomy specimens. Ann Surg 2011;253;271–278.
Barbour AP, Jones M, Brown I et al.. Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol 2010;17:2494–2502.
Rice TW, Zuccaro G Jr, Adelstein DJ et al.. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 1998;65:787–792.
Yajin S, Murakami G, Takeuchi H et al.. The normal configuration and interindividual differences in intramural lymphatic vessels of the esophagus. J Thorac Cardiovasc Surg 2009;137:1406–1414.
Gebski V, Burmeister B, Smithers BM et al.. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226–234.
Cunningham D, Allum WH, Stenning SP et al.. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.
Choi J, Kim SG, Kim JS et al.. Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 2010;24:1380–1386.
Waxman I. EUS and EMR/ESD: is EUS in patients with Barrett's esophagus with high-grade dysplasia or intramucosal adenocarcinoma necessary prior to endoscopic mucosal resection? Endoscopy 2006;38(Suppl 1):S2–4.
Liberale G, Van Laethem JL, Gay F et al.. The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol 2004;30:942–947.
Shimpi RA, George J, Jowell P, Gress FG. Staging of esophageal cancer by EUS: staging accuracy revisited. Gastrointest Endosc 2007;66:475–482.
Pech O, Gunter E, Dusemund F et al.. Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer. Endoscopy 2010;42:456–461.
Young PE, Gentry AB, Acosta RD et al.. Endoscopic ultrasound does not accurately stage early adenocarcinoma or high-grade dysplasia of the esophagus. Clin Gastroenterol Hepatol 2010;8:1037–1041.
Abela JE, Going JJ, Mackenzie JF et al.. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol 2008;103:850–855.
Garud SS, Keilin S, Cai Q, Willingham FF. Diagnosis and management of Barrett's esophagus for the endoscopist. Therap Adv Gastroenterol 2010;3:227–238.
Kara MA, Ennahachi M, Fockens P et al.. Detection and classification of the mucosal and vascular patterns (mucosal morphology) in Barrett's esophagus by using narrow band imaging. Gastrointest Endosc 2006;64:155–166.
Sharma P, Bansal A, Mathur S et al.. The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus. Gastrointest Endosc 2006;64:167–175.
Seewald S, Ang TL, Groth S et al.. Detection and endoscopic therapy of early esophageal adenocarcinoma. Curr Opin Gastroenterol 2008;24:521–529.
Pohl H, Koch M, Khalifa A et al.. Evaluation of endocytoscopy in the surveillance of patients with Barrett's esophagus. Endoscopy 2007;39:492–496.
Isenberg G, Sivak MV Jr, Chak A et al.. Accuracy of endoscopic optical coherence tomography in the detection of dysplasia in Barrett's esophagus: a prospective, double-blinded study. Gastrointest Endosc 2005;62:825–831.
Qi X, Sivak MV, Isenberg G et al.. Computer-aided diagnosis of dysplasia in Barrett's esophagus using endoscopic optical coherence tomography. J Biomed Opt 2006;11:044010.
Kiesslich R, Gossner L, Goetz M et al.. In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol 2006;4:979–987.
Dunbar KB, Okolo P III, Montgomery E, Canto MI. Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc 2009;70:645–654.
- Search Google Scholar
- Export Citation
. Dunbar KB Okolo P III Montgomery E Canto MI Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc 2009; 70: 645– 654.
Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043–2053.
Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 1988;83:291–294.
Sharma P, Falk GW, Weston AP et al.. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:566–572.
Conio M, Blanchi S, Lapertosa G et al.. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003;98:1931–1939.
Curvers WL, ten Kate FJ, Krishnadath KK et al.. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010;105:1523–1530.
Dent J. Barrett's esophagus: a historical perspective, an update on core practicalities and predictions on future evolutions of management. J Gastroenterol Hepatol 2011;26(Suppl 1):11–30.
Pellegrini CA, Pohl D. High-grade dysplasia in Barrett's esophagus: surveillance or operation? J Gastrointest Surg 2000;4:131–134.
Ferguson MK, Naunheim KS. Resection for Barrett's mucosa with high-grade dysplasia: implications for prophylactic photodynamic therapy. J Thorac Cardiovasc Surg 1997;114:824–829.
Stein HJ, Feith M, Bruecher BL et al.. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005;242:566–573.
Gasper WJ, Glidden DV, Jin C et al.. Has recognition of the relationship between mortality rates and hospital volume for major cancer surgery in California made a difference?: a follow-up analysis of another decade. Ann Surg 2009;250:472–483.
Patti MG, Corvera CU, Glasgow RE, Way LW. A hospital's annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg 1998;2:186–192.
Menon D, Stafinski T, Wu H et al.. Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy. BMC Gastroenterol 2010;10:111.
Wang KK, Wongkeesong M, Buttar NS. American Gastroenterological Association technical review on the role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 2005;128:1471–1505.
Chennat J, Waxman I. Endoscopic treatment of Barrett's esophagus: from metaplasia to intramucosal carcinoma. World J Gastroenterol 2010;16:3780–3785.
Kantsevoy SV, Adler DG, Conway JD et al.. Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc 2008;68:11–18.
Chennat J, Konda VJ, Ross AS et al.. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma—an American single-center experience. Am J Gastroenterol 2009;104:2684–2692.
Prasad GA, Wu TT, Wigle DA et al.. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 2009;137:815–823.
Pech O, Behrens A, May A et al.. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008;57:1200–1206.
Madisch A, Miehlke S, Bayerdorffer E et al.. Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation. World J Gastroenterol 2005;11:1182–1186.
Mork H, Al-Taie O, Berlin F et al.. High recurrence rate of Barrett's epithelium during long-term follow-up after argon plasma coagulation. Scand J Gastroenterol 2007;42:23–27.
Van Laethem JL, Peny MO, Salmon I et al.. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000;46:574–577.
Allison H, Banchs MA, Bonis PA, Guelrud M. Long-term remission of nondysplastic Barrett's esophagus after multipolar electrocoagulation ablation: report of 139 patients with 10 years of follow-up. Gastrointest Endosc 2011;73:651–658.
Polese L, Angriman I, Scarpa M et al.. Diode laser treatment of Barrett's esophagus: long-term results. Lasers Med Sci 2011;26:223–228.
Fisher RS, Bromer MQ, Thomas RM et al.. Predictors of recurrent specialized intestinal metaplasia after complete laser ablation. Am J Gastroenterol 2003;98:1945–1951.
Weston AP, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma. Am J Gastroenterol 2002;97:2998–3006.
Wang KK, Lutzke L, Borkenhagen L et al.. Photodynamic therapy for Barrett's esophagus: does light still have a role? Endoscopy 2008;40:1021–1025.
Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003;58:183–188.
Shaheen NJ, Sharma P, Overholt BF et al.. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277–2288.
Sharma VK, Wang KK, Overholt BF et al.. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007;65:185–195.
Fleischer DE, Overholt BF, Sharma VK et al.. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc 2008;68:867–876.
Fleischer DE, Overholt BF, Sharma VK et al.. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010;42:781–789.
Bulsiewicz WJ, Shaheen NJ. The role of radiofrequency ablation in the management of Barrett's esophagus. Gastrointest Endosc Clin N Am 2011;21:95–109.
Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007;117:524–529.
Shaheen NJ, Greenwald BD, Peery AF et al.. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010;71:680–685.
Pouw RE, Gondrie JJ, Sondermeijer CM et al.. Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg 2008;12:1627–1636.
Pouw RE, Wirths K, Eisendrath P et al.. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010;8:23–29.
Pouw RE, Gondrie JJ, Rygiel AM et al.. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett's esophagus containing neoplasia. Am J Gastroenterol 2009;104:1366–1373.
van Vilsteren FG, Pouw RE, Seewald S et al.. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011;60:765–773.
Biddlestone LR, Barham CP, Wilkinson SP et al.. The histopathology of treated Barrett's esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998;22:239–245.
Overholt BF, Dean PJ, Galanko JA, Lightdale CJ. Does ablative therapy for Barrett esophagus affect the depth of subsequent esophageal biopsy as compared with controls? J Clin Gastroenterol 2010;44:676–681.
Dua KS, Merrill JT, Komorowski R. Neosquamous epithelium after Barrett's ablation: cause for concern? Gastrointest Endosc, in press.